A recent study examining gout and chronic kidney disease found that achieving a serum urate level below 6 mg/dL with urate-lowering therapy does not increase the risk of severe or end-stage kidney disease...
A study assesses whether the dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin reduces ischemic events in diabetes and kidney disease.
In this respiratory disease roundup, experts examine the rising cases of human metapneumovirus in China, new research on COVID-19’s long-term effects on kidney function, the effectiveness of...
This phase 3 study demonstrated that roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is noninferior to rHuEPO-α in improving hemoglobin levels for chemotherapy-induced anemia,...
Researchers developed a cohort study of more than 14,000 participants to determine whether there is an association between statin initiation and a reduced risk of mortality and major adverse cardiovascular...
Oxalate nephropathy is a commonly underrecognized cause of chronic kidney disease and end-stage kidney disease with multiple etiologies, including primary hyperoxaluria, enteric hyperoxaluria, or ingestion...
Researchers set out to determine whether renal function could be used as both a predictor of relapse risk for patients with their first onset of aquaporin-4 (AQP4)-immunoglobulin G (IgG)-seropositive...
Individuals with primary hyperoxaluria type 1 are at an increased risk of urinary stone disease, nephrocalcinosis, and chronic kidney disease due to increased hepatic oxalate production. Researchers...
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
Did you watch our Multidisciplinary Roundtable on managing nutrition in patients with chronic kidney disease? Here are some highlights that you may have missed.
